Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis

Martins-Branco, Diogo; Marta, Guilherme Nader; Vuger, Ana Tečić; Debien, Véronique; Ameye, Lieveke; Brandão, Mariana; Punie, Kevin; Loizidou, Angela; Willard-Gallo, Karen; Spilleboudt, Chloé; Awada, Ahmad; Piccart‐Gebhart, Martine; Azambuja, Evandro de

doi:10.1007/s00432-022-04185-w

Cited by 9 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Along the same lines, large cancer SARS-CoV-2 studies report a progressive waning of antibody responses to SARS-CoV-2 vaccination with time, especially in patients with cancer on active chemotherapy, with a subsequent risk of breakthrough infections. 7,[29][30][31] However, studies demonstrated that patients with solid tumors, and breast cancer in particular, achieve an improved immunologic response to SARS-CoV-2 vaccination compared with patients with hematologic malignancies, 27,32,33 while some evidence reported similar levels of postvaccination neutralizing antibodies in patients with breast cancer receiving CDK4/6 inhibitor treatment in comparison with matched healthy subjects. 34 In view of published evidence supporting a nonuniversally consistent negative prognostic value of recent SACT, and particularly of chemotherapy, 3,4,13,18,[35][36][37] our propensity score-matched analysis showed no detrimental effect for the recent receipt of SACT and chemotherapy on COVID-19-related outcomes.…”

Section: Discussionmentioning

confidence: 99%

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

Tagliamento

Gennari

Lambertini

et al. 2023

JCO

View full text Add to dashboard Cite

PURPOSE Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice. METHODS We compared COVID-19 morbidity and mortality among patients with breast cancer across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December 1, 2020-December 14, 2021), and Omicron (December 15, 2021-January 31, 2022) phases using OnCovid registry participants (ClinicalTrials.gov identifier: NCT04393974 ). Twenty-eight-day case fatality rate (CFR28) and COVID-19 severity were compared in unvaccinated versus double-dosed/boosted patients (vaccinated) with inverse probability of treatment weighting models adjusted for country of origin, age, number of comorbidities, tumor stage, and receipt of systemic anticancer therapy within 1 month of COVID-19 diagnosis. RESULTS By the data lock of February 4, 2022, the registry counted 613 eligible patients with breast cancer: 60.1% (n = 312) hormone receptor–positive, 25.2% (n = 131) human epidermal growth factor receptor 2–positive, and 14.6% (n = 76) triple-negative. The majority (61%; n = 374) had localized/locally advanced disease. Median age was 62 years (interquartile range, 51-74 years). A total of 193 patients (31.5%) presented ≥ 2 comorbidities and 69% (n = 330) were never smokers. In total, 392 (63.9%), 164 (26.8%), and 57 (9.3%) were diagnosed during the prevaccination, Alpha-Delta, and Omicron phases, respectively. Analysis of CFR28 demonstrates comparable estimates of mortality across the three pandemic phases (13.9%, 12.2%, 5.3%, respectively; P = .182). Nevertheless, a significant improvement in outcome measures of COVID-19 severity across the three pandemic time periods was observed. Importantly, when reported separately, unvaccinated patients from the Alpha-Delta and Omicron phases achieved comparable outcomes to those from the prevaccination phase. Of 566 patients eligible for the vaccination analysis, 72 (12.7%) were fully vaccinated and 494 (87.3%) were unvaccinated. We confirmed with inverse probability of treatment weighting multivariable analysis and following a clustered robust correction for participating center that vaccinated patients achieved improved CFR28 (odds ratio [OR], 0.19; 95% CI, 0.09 to 0.40), hospitalization (OR, 0.28; 95% CI, 0.11 to 0.69), COVID-19 complications (OR, 0.16; 95% CI, 0.06 to 0.45), and reduced requirement of COVID-19–specific therapy (OR, 0.24; 95% CI, 0.09 to 0.63) and oxygen therapy (OR, 0.24; 95% CI, 0.09 to 0.67) compared with unvaccinated controls. CONCLUSION Our findings highlight a consistent reduction of COVID-19 severity in patients with breast cancer during the Omicron outbreak in Europe. We also demonstrate that even in this population, a complete severe acute respiratory syndrome coronavirus 2 vaccination course is a strong determinant of improved morbidity and mortality from COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

Tagliamento

Gennari

Lambertini

et al. 2023

JCO

View full text Add to dashboard Cite

show abstract

“…Ainsley Ryan Yan Bin Lee et al [33] presented similar results in their metaanalysis. Martins-Branco et al pointed out that the seroprevalence rate in patients with solid tumors was 94% (95% CI, 88-97%) [34]. An important consequence of immunosenescence is an impaired response to vaccination, characterized by reduced titers of vaccine-specific antibodies, shorter duration of measurable vaccine-specific antibodies, and reduced quality and affinity of antibody responses [35,36].…”

Section: Discussionmentioning

confidence: 99%

Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients

et al. 2023

View full text Add to dashboard Cite

Cancer is an important public health problem. Prostate cancer is one of the most common cancers among men. In Poland, the incidence of this type of cancer is constantly growing. Considering the appearance of a new coronavirus in December 2019 (SARS-CoV-2) and the fact that oncology patients, including those with prostate cancer, are particularly vulnerable to infection, it is recommended to get vaccinated against COVID-19. In our study, we determined the level and prevalence of antibodies against SARS-CoV-2 IgG in patients with prostate cancer compared to the control group and whether the patients’ ages affected the level of antibodies. PCa patients and controls were divided into two age groups: 50–59 years and 60–70 years. We also analyzed the level of antibodies in patients belonging to the relevant risk groups for prostate cancer (the European Society of Urology risk group classification of prostate cancer). For the study, we used the Microblot-Array COVID-19 IgG test to detect antibodies against the three main SARS-CoV-2 antigens: NCP, RBD, and S2. Our results showed that prostate cancer patients had significantly lower levels of anti-SARS-CoV-2 IgG antibodies compared to controls. In addition, age also affected the decrease in the number of IgG antibodies. The level of antibodies in the intermediate/high-risk group was lower compared to the low-risk group.

show abstract

“…Haematological malignancy had significantly higher risk of death than prostate cancer or other solid tumors. Haematological malignancies had already been associated with worst COVID-19 outcome ( 36 , 37 ) and reduced immune responses to the vaccination contributing to ongoing unfavorable COVID-19 outcomes ( 13 , 18 , 38 ). The HR for “no treatment” vs chemotherapy with regard to hospitalization was 2.81, this result is consistent with those of CCC19 ( 24 ), which suggested that cancer treatment could be continued during the pandemic in view of the benefit-risk ratio, even for cytotoxic chemotherapy if clinically indicated.…”

Section: Discussionmentioning

confidence: 99%

“…Fortunately, owing to a massive global effort, several highly effective vaccines, particularly mRNA-based (BNT162b2 and mRNA-1273) and adenovirus-vectored vaccines (ChAdOx1 nCoV19, Ad26.COV2-S and Gam-COVID-Vac), have been developed at an unprecedented speed ( 12 , 13 , 14 , 15 ). These vaccines were safe and effective in patients with cancer ( 13 , 16 , 17 , 18 ). Moreover, several patients experienced natural SARS-CoV2 infection and acquired immune protection ( 11 , 13 ).…”

Section: Introductionmentioning

confidence: 99%

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

et al. 2023

View full text Add to dashboard Cite

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis

Cited by 9 publications

References 10 publications

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

Contact Info

Product

Resources

About